Education
About Us
Working with TipRanks
Follow Us
Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA
RESEARCH TOOLSreports
Top Page
Sonoma Pharmaceuticals
(NASDAQ:SNOA)
51Neutral
Sonoma Pharmaceuticals (SNOA) vs. S&P 500 (SPY)
Market Cap
$5.49M
Dividend YieldN/A
Average Volume (3M)3.05M
Price to Earnings (P/E)―
Beta (1Y)2.62
Revenue Growth13.51%
EPS Growth78.93%
CountryUS
Employees171
SectorHealthcare
Sector Strength78
IndustryPharmaceuticals
Share Statistics
EPS (TTM)-3.93
Shares Outstanding1,615,765
10 Day Avg. Volume9,086,247
30 Day Avg. Volume3,053,854
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.43
Price to Cash Flow (P/CF)2.40
P/FCF Ratio2.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Sonoma Pharmaceuticals Business Overview & Revenue Model
Company DescriptionSonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.
How the Company Makes MoneySonoma Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include the direct sales of its dermatological and advanced tissue care products to healthcare providers, pharmacies, and consumers. Additionally, Sonoma engages in partnerships and distribution agreements with other companies to expand its market reach and product availability. These partnerships may involve licensing deals or co-marketing arrangements that contribute to its earnings by leveraging the partner's distribution network and market presence. The company also invests in research and development to innovate new products and improve existing ones, which can lead to increased sales and revenue growth over time.
Sonoma Pharmaceuticals Financial Statement Overview
Summary
Sonoma Pharmaceuticals faces financial challenges with declining revenues and persistent losses. Although leverage is low, the company's reliance on external financing and shrinking equity base are concerning. Improvements in operational efficiency and revenue growth are essential for future stability.Income Statement
Sonoma Pharmaceuticals shows a consistent decline in revenue over the past years, which is concerning. The gross profit margin decreased significantly, indicating potential issues in cost management or pricing strategies. The company is also experiencing persistent net losses, as reflected in the negative EBIT and EBITDA margins.45
Neutral
Balance Sheet
The debt-to-equity ratio is low, which suggests conservative leverage. However, the continuous decrease in stockholders' equity and total assets raises concerns about the company’s financial stability and ability to sustain operations without further dilution of equity or taking on debt.50
Neutral
Cash Flow
Cash flow from operations has improved slightly in the TTM period, but free cash flow remains low. The company is heavily reliant on financing activities to maintain liquidity, which could pose risks if external financing becomes less accessible.40
Negative
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 10.58M | 12.73M | 13.27M | 12.63M | 18.63M | 18.94M | Gross Profit |
| 3.72M | 4.75M | 4.48M | 3.99M | 6.56M | 8.33M | EBIT |
| -3.29M | -4.70M | -4.57M | -5.89M | -3.45M | -6.67M | EBITDA |
| -3.21M | -4.53M | -4.45M | -5.70M | -3.22M | -3.22M | Net Income Common Stockholders |
| -2.60M | -4.83M | -5.15M | -5.09M | -4.62M | -2.95M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.13M | 3.13M | 3.82M | 7.40M | 4.22M | 3.69M | Total Assets |
| 14.89M | 14.74M | 16.23M | 18.84M | 14.99M | 14.56M | Total Debt |
| 608.00K | 608.00K | 849.00K | 1.37M | 2.67M | 1.48M | Net Debt |
| -2.52M | -2.52M | -2.97M | -6.03M | -1.54M | -2.21M | Total Liabilities |
| 8.76M | 8.60M | 8.25M | 10.15M | 9.62M | 5.86M | Stockholders Equity |
| 6.14M | 6.14M | 7.98M | 8.70M | 5.36M | 8.71M |
| Cash Flow | Free Cash Flow | ||||
| 1.05M | -2.42M | -6.42M | -4.38M | -3.56M | -4.80M | Operating Cash Flow |
| 1.07M | -2.40M | -6.15M | -4.25M | -3.38M | -4.59M | Investing Cash Flow |
| -10.00K | -2.00K | -258.00K | -99.00K | 388.00K | 3.64M | Financing Cash Flow |
| 2.77M | 1.68M | 2.49M | 7.40M | 3.31M | 1.03M |
Sonoma Pharmaceuticals Technical Analysis
Positive
3.51
Price Trends
2.58
Positive
2.69
Positive
3.63
Negative
Market Momentum
0.09
Negative
75.43
Negative
58.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNOA, the sentiment is Positive. The current price of 3.51 is above the 20-day moving average (MA) of 2.46, above the 50-day MA of 2.58, and below the 200-day MA of 3.63, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 75.43 is Negative, neither overbought nor oversold. The STOCH value of 58.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNOA.
Sonoma Pharmaceuticals Risk Analysis
Sonoma Pharmaceuticals disclosed 34 risk factors in its most recent earnings report. Sonoma Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sonoma Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.49M | ― | -64.83% | ― | 13.51% | 78.93% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
47 Neutral | $34.20M | ― | -48.42% | ― | -93.70% | -163.86% | |
39 Underperform | $16.20M | ― | -25.70% | ― | ― | 86.44% | |
35 Underperform | $13.84M | ― | -52.85% | ― | ― | 8.99% |
* Healthcare Sector Average
Performance Comparison
SNOA
Sonoma Pharmaceuticals
3.51
0.77
28.10%
SCYX
SCYNEXIS
0.91
-0.62
-40.52%
XTLB
XTL Biopharmaceuticals Ltd. Sponsored ADR
1.24
0.29
30.53%
CTXR
Citius Pharmaceuticals
1.59
-16.42
-91.17%
Sonoma Pharmaceuticals Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Sonoma Pharmaceuticals Ends EMC Pharma Agreement
Neutral
Nov 21, 2024
Sonoma has terminated its exclusive agreement with EMC Pharma due to EMC’s failure to meet minimum purchase requirements, allowing Sonoma to resume direct sales of its dermatological and eye care products in the U.S. This decision is part of the company’s strategy to enhance its market presence, despite potential risks and uncertainties that could affect its future financial performance.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.